This grant, offered by the National Cancer Institute (NCI) and National Institutes of Health (NIH) through the Cancer Diagnosis Program (CDP) and Cancer Therapy Evaluation Program (CTEP), is for validating the clinical utility of new molecular diagnostics in cancer. It encourages R21 applications from institutions to assess how well these diagnostics predict patient prognosis, response to therapy, or toxicity. The primary purpose is to transition promising candidate biomarkers from initial observations into validated diagnostics suitable for use in clinical trials. This program supports pilot research projects that utilize tumor specimens linked to specific treatment and clinical outcome information, ultimately aiming to improve clinical decision-making for cancer patients. This opportunity does not fund molecular diagnostics discovery.
Opportunity ID: 130954
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PA-12-014 |
| Funding Opportunity Title: | Validation of Molecular Diagnostics to Predict Patient Outcomes Using Specimens from Multi-Site Cancer Trials (R21) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.394 — Cancer Detection and Diagnosis Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 16, 2011 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Jan 07, 2015 |
| Current Closing Date for Applications: | Jan 07, 2015 |
| Archive Date: | Feb 07, 2015 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $275,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses County governments Native American tribal governments (Federally recognized) Special district governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Independent school districts Private institutions of higher education Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are t eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), encourages the submission of Exploratory/Developmental Research Project Grant (R21) applications from institutions and organizations to validate the clinical utility of new molecular diagnostics for determining prognosis or predicting response to therapy or toxicity for cancer. The Cancer Diagnosis Program (CDP) and the Cancer Therapy Evaluation Program (CTEP) at the NCI are cooperatively sponsoring this FOA with the purpose to transition of candidate biomarkers from initial correlative observations into diagnostics that are suitable for use in clinical trials to assess the clinical validity of a marker. This program will support pilot research projects to improve clinical decision-making in the care of cancer patients and as such will support studies that use tumor specimens linked to specific treatment and clinical outcome information. This FOA is not appropriate for molecular diagnostics discovery projects. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PA-12-014.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| ADOBE-FORMS-B2 | ADOBE-FORMS-B2 | PKG00085770 | Jan 16, 2012 | Sep 24, 2013 | View | |
| FORMS-C | Use for due dates after 9/24/2013 | PKG00181465 | Sep 16, 2013 | Jan 07, 2015 | View |
Package 1
Mandatory forms
130954 RR_SF424_1_2-1.2.pdf
130954 PerformanceSite_1_4-1.4.pdf
130954 RR_OtherProjectInfo_1_3-1.3.pdf
130954 RR_KeyPersonExpanded_1_2-1.2.pdf
130954 PHS398_CoverPageSupplement_1_4-1.4.pdf
130954 PHS398_ResearchPlan_1_3-1.3.pdf
130954 PHS398_Checklist_1_3-1.3.pdf
Optional forms
130954 RR_SubawardBudget30-1.2.pdf
130954 PHS398_ModularBudget_1_2-1.2.pdf
130954 RR_Budget-1.1.pdf
130954 PHS_CoverLetter_1_2-1.2.pdf
Package 2
Mandatory forms
130954 RR_SF424_2_0-2.0.pdf
130954 PHS398_ResearchPlan_2_0-2.0.pdf
130954 PHS398_CoverPageSupplement_2_0-2.0.pdf
130954 RR_KeyPersonExpanded_2_0-2.0.pdf
130954 RR_OtherProjectInfo_1_3-1.3.pdf
130954 PerformanceSite_2_0-2.0.pdf
Optional forms
130954 RR_SubawardBudget30_1_3-1.3.pdf
130954 PlannedReport-1.0.pdf
130954 PHS398_CumulativeInclusionReport-1.0.pdf
130954 PHS398_ModularBudget_1_2-1.2.pdf
130954 RR_Budget_1_3-1.3.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
